UPDATE IN STEMI CARE


Robert T. Pyo Associate Professor Stony Brook University Renaissance School of Medicine


When and What to Treat **Stable Patients Shock Patients** How to Treat Pharmacotherapy **Technical Considerations** Systems of Care **Primary PCI** Fibrinolysis and Pharmacoinvasive Strategy 56 year old male presents with 2 hours onset of chest pain.

Ekg is significant for ST elevations in the anterolateral leads.

His blood pressure is stable 150/90 and his heart rate is 89

He is a past smoker and his past medical history is significant for hypertension





What to treat? LAD Only? Both LAD and RCA? Anti-platelet Therapy Plavix? Ticagrelor? Prasugrel? How Long? 12 months? ≥ 12 months?

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction

Class I

1. Primary PCI should be performed in patients with STEMI and ischemic symptoms of less than 12 hours' duration.^{17,50,51} (Level of Evidence: A)

Class IIa

1. PCI is reasonable in a noninfarct artery at a time separate from primary PCI in patients with intermediate- or high-risk findings on noninvasive testing._{58,141,142} (*Level of Evidence: B*)


Class III: Harm

1. PCI should not be performed in a noninfarct artery at the time of primary PCI in patients with STEMI who are hemodynamically stable.⁵⁸⁻⁶⁰ (*Level of Evidence: B*)

Complete Revascularization with Multivessel PCI for Myocardial Infarction (COMPLETE TRIAL)

Cardiovascular death or myocardial infarction

Cardiovascular death, Myocardial infarction, or Ischemia-driven revascularization



cularization


B Second Coprimary Outcome

N Engl J Med. 2019 Oct 10;381(15):1411-1421.

					Events,	Events,	%
Study	Year			RR (95% CI)	Treatment	Control	Weig
PRAGUE 13	2015			1.15 (0.61, 2.19)	17/106	15/108	20.79
DANAMI3-PRIMULTI	2015			0.80 (0.45, 1.41)	20/314	25/313	22.54
CvLPRIT	2015			0.39 (0.12, 1.21)	4/150	10/146	11.76
PRAMI	2013			0.40 (0.20, 0.79)	11/234	27/231	19.96
Ghani	2012		••••>	16.91 (1.04, 274.86)	16/79	0/40	2.81
Politi	2010			0.52 (0.24, 1.10)	8/65	20/84	18.29
HELP AMI	2004			0.65 (0.06, 6.77)	2/52	1/17	3.85
Overall (I-squared = 50.5%	6, p = 0.059)	\Diamond		0.69 (0.42, 1.12)	78/1000	98/939	100.0
NOTE: Weights are from ra	andom effects analysis						
Complete R	evasc Asso	.1 1 ciated with	10 Complete F	Revasc Assc	ciated w	ith	
Lower Incide			•	ncidence Mo		r MI	ry 7

Catheter Cardiovasc Interv. 2016 Oct;88(4):501-505

Complete Revascularization with Multivessel PCI for Myocardial Infarction (COMPLETE TRIAL)



2013 Recommendation	2015 Focused Update Recommendation	Comment
Class III: Harm PCI should not be performed in a noninfarct artery at the time of primary PCI in patients with STEMI who are hemodynamically stable (11–13). (Level of Evidence: B)	Class IIb PCI of a noninfarct artery may be considered in selected patients with STEMI and multivessel disease who are hemodynamically stable, either at the time of primary PCI or as a planned staged procedure (11-24). (Level of Evidence: B-R)	Modified recommendation (changed class from "III: Harm" to "IIb" and expanded time frame in which multivessel PCI could be performed).


PCI indicates percutaneous coronary intervention; and STEMI, ST-elevation myocardial infarction.

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction

Class III: Harm 1. PCI should not be performed in a noninfarct artery at the time of primary PCI in patients with STEMI who are hemodynamically stable.₅₈₋₆₀ (*Level of Evidence: B*)

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation


Non-IRA PCI during the index procedure should be considered in patients with cardiogenic shock.





Integrating the results of the CULPRIT-SHOCK trial in the 2017 ESC ST-elevation myocardial infarction guidelines

"Based on the new robust evidence from the adequately powered CULPRIT-SHOCK trial, it is now the opinion of the 2017 STEMI TF (Task Force) that in patients with cardiogenic shock complicating STEMI, primary PCI should be restricted to the IRA."

PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock







	Complete	Culprit Only		
Contrast Vol	190ml	250ml	P<.001	
Fluoro Time	13min	19min	P<.001	
No Difference:				

- MCS Use ۲
- **Duration of Catecholamine Use** ٠
- Days to Stabilization ٠

N Engl J Med. 2017 Dec 21;377(25):2419-2432.

Primary PCI Should be the preferred Treatment for the Culprit Artery in STEMI Patients

In Stable Patients

✓ PCI of the Non-Culprit Artery Should Be Considered

✓ PCI of the Non-Culprit Artery Can be done during the index procedure or staged In Shock Patients

✓ PCI of only the Culprit Artery is Recommended

✓ PCI of the Non-Culprit Artery can be considered in special circumstances

Duration of DAPT Therapy After PCI

Class I Indications

1. Aspirin 162 to 325 mg should be given before primary PCI. (*Level of Evidence: B*)

2. After PCI, aspirin should be continued indefinitely. (Level of Evidence: A)

3. A loading dose of a P2Y12 receptor inhibitor should be given as early as possible or at time of primary PCI to patients with STEMI. Options include

a. Clopidogrel 600 mg (Level of Evidence: B); or

b. Prasugrel 60 mg (Level of Evidence: B); or

c. Ticagrelor 180 mg (Level of Evidence: B)

4. P2Y12 inhibitor therapy should be given for 1 year to patients with STEMI who receive a stent (bare-metal or drug-eluting) during primary PCI using the following maintenance doses:

a. Clopidogrel 75 mg daily (Level of Evidence: B); or

b. Prasugrel 10 mg daily (*Level of Evidence: B*); or

c. Ticagrelor 90 mg twice a day (Level of Evidence: B)

Circulation. 2013 Jan 29;127(4):e362-425.


2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease

Harm

Recommendations for Duration of DAPT in Patients With ACS Treated With PCI

COR	LOE	Recommendations
į.	B-R	In patients with ACS (NSTE-ACS or STEMI) treated with DAPT after BMS or DES implantation. P2Y ₁₂ inhibitor therapy (cloud get (p) signal, or a captofst) should be given for at least 12 months. ^{10,30–55,72,96–96}
н	B-NR	In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended. ^{56–60,75–78}
lla	B-R	In patients with ACS (NSTE-ACS or STEMI) treated with APT after approximation start implantation, it is reasonable as stica grade impleference it coordogrel for maintenance P2Y ₁₂ inhibitor therapy. ^{53,72}
lla	B-R	In patients with ACS (NSTE-ACS or STEMI) treated with DAPT after coronary stent implantation who remar a Pg, 25k for beeding complications and who do not have a historic stroke or TIA, it is reasonable to choose prasugrel over clopidogrel for maintenance P2Y ₁₂ inhibitor therapy. ^{54,55}

Recommendations for Duration of DAPT in Patients With ACS Treated With PCI



with a prior history of stroke or TIA.54

Goals for DAPT after PCI in Patients with STEMI




Local Effect at the Stent: Prevention of In-Stent Thrombosis Systemic Effect: Prevention of Ischemic Events For High Risk Patient

Cypher" Stent	Improved Polymer Performance Reduced Inflammatory Response	Synergy''' Stent
	Improved Elution of Drugs Improved Stent Strut Design	
Bx Velocity" Stent	Improved Delivery	
I40 μm Stainless Steel	Less Chance to Close Side Branches	74 µm Platinum Chromium

The drug eluting stent is listed above, with the corresponding bare metal version annotated below. The material that the stents are manufactured from and strut thickness are noted. These are drawn to scale. Strut thickness refers to the axis measured as if from the lumen to the vessel wall.

Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI

1-Month DAPT (n = 1,392)	3-Month DAPT (n = 1,972)
950/1,392 (68.2)	1,292/1,972 (65.5)
617/1,392 (44.3)	805/1,972 (40.8)
201/1,392 (14.4)	313/1,972 (15.9)
145/1,392 (10.4)	223/1,972 (11.3)
116/1,392 (8.3)	157/1,972 (8.0)
55/1,392 (4.0)	60/1,972 (3.0)
46/1,392 (3.3)	57/1,972 (2.9)
1.5 ± 0.7	1.5 ± 0.7
917/1,392 (65.9)	1,283/1,972 (65.1)
475/1,392 (34.1)	689/1,972 (34.9)
245/1,392 (17.6)	141/1,972 (7.2)
230/1,392 (16.5)	572/1,972 (29.0)
	(n = 1,392) 950/1,392 (68.2) 617/1,392 (44.3) 201/1,392 (14.4) 145/1,392 (10.4) 116/1,392 (8.3) 55/1,392 (4.0) 46/1,392 (3.3) 1.5 \pm 0.7 917/1,392 (65.9) 475/1,392 (34.1) 245/1,392 (17.6)



Propensity score stratified mean (PS-SM) rates of all-cause death or myocardial infarction from 1 to 12 months post-PCI in patients receiving 1-month DAPT vs 3-month DAPT (A), and landmark analysis at 90 days (B). P value is from superiority test with a 1-sided alpha of 0.025. Error bars are SEM. DAPT – dual antiplatelet therapy; PCI = percutaneous coronary intervention.


No difference in outcome 1 month vs 3 months DAPT at 1 year follow up

J Am Coll Cardiol. 2021 Nov 23;78(21):2060-2072.

Short DAPT Therapy in Patients with High Bleed Risk

Baseline Characteristics of Patients at HBR

30 Days DAPT: (clopidogrel/prasugrel/ticagrelor) + Aspirin



The number of patients fulfilling each high bleeding risk (HBR) criterion is shown in decreasing order. There was a considerable overlap among HBR criteria, with 643 patients (78%) fulfilling 1, 330 (40%) 2, and 65 (8%) ≥3 HBR gualifying features. NSAID – nonsteroidal antiinflammatory drugs.


JACC Cardiovasc Interv. 2016 Mar 14;9(5):426-36.

360

351

314

Duration of DAPT Therapy After PCI




Increased Ischemic Risk/Risk of Stent Thrombosis (may favor longer-duration DAPT)	Increased Bleeding Risk (may favor shorter-duration DAPT)
Increased ischemic risk	History of prior bleeding
Advanced age	Oral anticoagulant therapy
ACS presentation	Female sex
Multiple prior MIs	Advanced age
Extensive CAD	Low body weight
Diabetes mellitus	CKD
CKD	Diabetes mellitus
Increased risk of stent thrombosis	Anemia
ACS presentation	Chronic steroid or NSAID therapy
Diabetes mellitus	
Left ventricular ejection fraction <40%	
First-generation drug-eluting stent	
Stent undersizing	
Stent underdeployment	
Small stent diameter	
Greater stent length	
Bifurcation stents	
In-stent restenosis	

ACS indicates acute coronary syndrome; CAD, coronary artery disease; CKD, chronic kidney disease; DAPT, dual antiplatelet therapy; MI, myocardial infarction; and NSAID, nonsteroidal anti-inflammatory drug.

Ticagrelor in Patients with Stable Coronary Disease and Diabetes

Less Events

More Bleeding




N Engl J Med. 2019 Oct 3;381(14):1309-1320.

Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial

Baseline Patient Characteristics by Stent Type

CV Death, MI, or Stroke (%)



MASTER DAPT #ESCCongress



Clinical presentation		
Stable angina — no. (%)	922 (40.2)	927 (40.6)
Silent ischemia — no. (%)	245 (10.7)	274 (12.0)
Non–ST-elevation myocardial infarction — no. (%)	595 (25.9)	558 (24.4)
ST-elevation myocardial infarction — no. (%)	273 (11.9)	265 (11.6)
Unstable angina — no. (%)	260 (11.3)	260 (11.4)
STEMI/NSTEMI	23.2%	23%
STEMI	11.9%	11.6%

Low percentage of patients who presented STEMI


✓ Patients should be treated with aspirin and P2Y12 Inhibitor

✓ Duration of DAPT therapy should be for at least one year

✓ In patients at high risk of bleeding, DAPT therapy can be shortened to six months

✓ In patients at high risk for Ischemic Events and Low Risk of Bleeding, DAPT May be Extended Beyond One Year

Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial




	Total	Radial (n/N [%])	Femoral (n/N [%])	HR (95% CI)	Primary outcome			
					p value			Interact
Age (years)								
<75	5986	87/3001 (2.9)	91/2985 (3-0)	0.95 (0.71-1.27)	0.73			0.79
≥75	1035	41/506 (8-1)	48/529 (9-1)	0.89 (0.58-1.34)	0-57			975
Sex								
Women	1861	36/908 (4-0)	48/953 (5.0)	0.78 (0.50-1.20)	0-25			0.36
Men	5160	92/2599 (3.5)	91/2561 (3-6)	0.99 (0.74-1.33)	0-97			0.30
BMI (kg/m²)								
<25	2152	44/1067 (4-1)	50/1085 (4.6)	0.89 (0.59-1.33)	0.57			
25-35	4386	73/2205 (3-3)	82/2181 (3-8)	0.88 (0.64-1.20)	0-42			0.83
>35	454	7/219 (3-2)	6/235 (2.6)	1.24 (0.42-3.70)	0-70			0.03
PCI in hospital								
No	2361	49/1196 (4-1)	49/1165 (4-2)	0.97 (0.65-1.44)	0.89			0.72
Yes	4660	79/2311 (3.4)	90/2349 (3-8)	0.89 (0.66-1.20)	0-45			0.72
Radial PCI volume	by operator	LANGER CONTRACTOR	to inclusion 444 (Sector)	SUPERIOR CONTRACTOR	101920740	1100		
≤70	2363	49/1164 (4-2)	46/1199 (3-8)	1-10 (0-74-1-65)	0-63			
71-142	2315	50/1158 (4-3)	57/1157 (4·9)	0.87 (0.60-1.27)	0-48			0.54
>142	2336	29/1182 (2-4)	36/1154 (3-1)	0.79 (0.48-1.28)	0-33			0.34
Radial PCI volume	by centre							
Lowest tertile	1920	33/958 (3-4)	40/962 (4-2)	0.83 (0.52-1.31)	0.42	· · · · · · · · · · · · · · · · · · ·		
Middle tertile	2846	77/1420 (5-4)	63/1426 (4-4)	1.23 (0.88-1.72)	0.22			0.021
Highest tertile	2255	18/1129 (1-6)	36/1126 (3-2)	0.49 (0.28-0.87)	0-015 -			0.021
Clinical diagnosis								
NSTE-ACS	5063	98/2552 (3-8)	87/2511 (3.5)	1-11 (0-83-1-48)	0-49			0.025
STEMI	1958	30/955 (3-1)	52/1003 (5-2)	0.60 (0.38-0.94)	0-026			0.023
Overall	7021	128/3507 (3.7)	139/3514 (4-0)	0.92 (0.72-1.17)	0.50			
					J050	575-54		
					0-25	1-00	4-00	
					Favo	urs radial Fav	ours femoral	

Lancet. 2011 Apr 23;377(9775):1409-20.

Radial Approach is Preferred


COR	LOE	RECOMMENDATIONS
1	A	1. In patients with ACS undergoing PCI, a radial approach is indicated in preference to a femoral approach to reduce the risk of death, vascular complications, or bleeding (1-4).
1	А	2. In patients with SIHD undergoing PCI, the radial approach is recommended to reduce access site bleeding and vascular complications (4-7).

Radial access is recommended over femoral access if performed by an experienced radial operator.^{143–145,180}





Circulation. 2022 Jan 18;145(3):e4-e17. Eur Heart J. 2018 Jan 7;39(2):119-177.

TAPAS











TASTE

TOTAL





N Engl J Med. 2015 Apr 9;372(15):1389-98.

2011/2013 Recommendation	2015 Focused Update Recommendations	Comments		
Class IIa Manual aspiration thrombectomy is reasonable for patients undergoing primary PCI (29-32). (Level of Evidence: B)	Ansal IIaClass IIbManual aspiration thrombectomy is reasonable for patients undergoing primary PCI (29-32). (Level of Evidence: B)The usefulness of selective and bailout aspiration thrombectomy in patients undergoing primary PCI is not well established (33-37). (Level of Evidence: C-LD)			
	Class III: No Benefit Routine aspiration thrombectomy before primary PCI is not useful (33-37). (Level of Evidence: A)	New recommendation ("Class III: No Benefit" added for <i>routine</i> aspiration thrombectomy before PCI).		

PCI indicates percutaneous coronary intervention; and LD, limited data.

Routine use of thrombus aspiration is not recommended.^{157,159}




Circulation. 2022 Jan 18;145(3):e4-e17.

Eur Heart J. 2018 Jan 7;39(2):119-177.

Systems for STEMI Care in India


	2009	2010	2011	2012
Total no. of primary PCI	5584	14271	20541	21343
% of Total interventions	9.79%	12.15%	13.48%	12.04%



Hub A: 24/7 Primary PCI Capable Hub B: PCI During Day Spoke C: Within 30 Min of PCI Capable Hospital Spoke D: More than 30 Min Away from PCI Capable Hospital


	Door to Ne	edle < 3	30 min Ph	armaco-invasive 3-24 hrs
Variable	10 min		10 min	
Onset of patient symptoms	Arrival of patient at hospital / ambulance	EGC	Lysis	
			Transport to PCI capable Hospita	
Variab l e	10 min 20		20-30 min	45-60 min
	Door	to Ballo	oon < 90 min	
	Total is	chemia '	Time < 120 mil	n


Indian Heart J. 2015 Sep-Oct;67(5):497-502.



(n = 1367)		o)	(n = 1053)		Overall, No. (%)		
Outcome	Preimplementation Phase (n = 413)	Postimplementation Phase (n = 954)	Preimplementation Phase (n = 485)	Postimplementation Phase (n = 568)	Preimplementation Phase (n = 898)	Postimplementation Phase (n = 1522)	P Value
In-hospital mortality (n = 2420)	15 (3.6)	49 (5.1)	37 (7.6)	36 (6.3)	52 (5.8)	85 (5.6)	.83
Stroke (n = 2420)	1 (0.2)	1 (0.1)	3 (0.6)	2 (0.4)	4 (0.5)	3 (0.2)	.27
Cardiogenic shock (n = 2420)	8 (1.9)	23 (2.4)	27 (5.6)	26 (4.6)	35 (3.9)	49 (3.2)	.38
Symptomatic ischemia (n = 2420)	1 (0.2)	6 (0.6)	15 (3.1)	10 (1.8)	16 (1.8)	16 (1.1)	.13
1-Year mortality (n = 2020)	48 (13.3)	100 (12.1)	86 (21.5)	79 (18.2)	134 (17.6)	179 (14.2)	.04

JAMA Cardiol. 2017;2(5):498-505.






Eur Heart J. 2018 Jan 7;39(2):119-177.

Observational Study: Pharmacoinvasive Strategy in Real Life

	All Patients			Propensity-Matched Patients			
	PI (n=708)	PPCI (n=8878)	P Value	PI (n=706)	PPCI (n=706)	P Value	
Symptom to first medical contact, min	60 (30–132)	80 (30-222)	<0.001	60 (30–132)	60 (30–150)	0.965	
Symptom to start of reperfusion therapy, min	165 (92–281)	255 (158-464)	< 0.001	165 (92–283)	241 (160–378)	<0.001	
First medical contact to start of reperfusion therapy, min	80 (30–145)	132 (77–220)	<0.001	80 (30–145)	145 (88–235)	<0.001	
Door to balloon, h	40.1 (8.7–75.9)	1.2 (0.9–1.7)	<0.001	40.1 (8.7–75.8)	1.3 (1.0–1.9)	<0.001	
PCI-related delay, min					105 (51–215)		

	All Patients			Propensity-Matched Patients			
	PI (n=708)	PPCI (n=8878)	P Value	PI (n=706)	PPCI (n=706)	<i>P</i> Value	
Fibrinolytic agent							
Tenecteplase	364 (51.4)	NA		364 (51.6)	NA		
Alteplase	290 (41.0)	NA		288 (40.8)	NA		
Urokinase	54 (7.6)	NA		54 (7.6)	NA		
Rescue PCI after fibrinolysis	271 (38.3)	NA		271 (38.4)	NA		
Urgent PCI after fibrinolysis	56 (7.9)	NA	56 (7.9)		NA		
Elective PCI after fibrinolysis	381 (53.8)	NA		379 (53.7)	NA		



Circ Cardiovasc Interv. 2016 Sep;9(9):e003508

Adjuvant Therapy

Fibrinolytic therapy

Recommendations	Class	Level
When fibrinolysis is the reperfusion strategy, it is recommended to initiate this treatment as soon as possible after STEMI diagnosis, preferably in the pre-hospital setting. ^{76,90,123,222}	1	(A)
A fibrin-specific agent (i.e. tenecteplase, alteplase, or reteplase) is recommended. ^{223,224}	1	В
A half-dose of tenecteplase should be considered in patients \geq 75 years of age. 121	lla	В
Antiplatelet co-therapy with fibrinolysis		
Oral or i.v. aspirin is indicated. ²¹³	T.	В
Clopidogrel is indicated in addition to aspirin. ^{325,226}	T	A
DAPT (in the form of aspirin plus a P2Y ₁₂ inhibitor ⁶) is indicated for up to 1 year in patients undergoing fibrinolysis and subsequent PCI.	1	c
Anticoagulation co-therapy with fibrinolysis		02
Anticoagulation is recommended in patients treated with lytics until revascularization (if performed) or for the duration of		A
 bospital stay up to 8 days, ^{199,224,227-233} The anticoagulant can be: Enoxaparin i.v. followed by s.c. (preferred over UFH),²²⁷⁻²³² 	Ĭ	A
 UFH given as a weight-adjusted i.v. bolus followed by infusion.⁷²⁴ 	4	B
 In patients treated with streptokinase: fondaparinux i.v. bolus followed by an s.c. dose 24 h later.^{199,233} 	Ila	в
Transfer after fibrinolysis		
Transfer to a PCI-capable centre following fibrinolysis is indicated in all patients immediately after fibrinolysis, 121, 124, 126-130, 224		A
Interventions following fibrinolysis		
Emergency angiography and PCI if indicated is recommended in patients with heart failure/shock. ^{124, 235}		A
Rescue PCI is indicated immediately when fibrinolysis has failed (<50% ST-segment resolution at 60–90 min) or at any time in the presence of haemodynamic or electrical instability, or worsening ischaemia. ^{121,124,236}	т	· A
Angiography and PCI of the IRA, if indicated, is recommended between 2 and 24 h after successful fibrinolysis. 125-128,234		A
Emergency angiography and PCI if needed is indicated in the case of recurrent ischaemia or evidence of reocclusion after initial successful fibrinolysis. ¹²⁴	- î	в

DAPT = dual antiplatelet therapy: RA = infarct-related artery; Iv. = intravenous; PCI = percutaneous coronary intervention; SBP = systolic blood pressure; s.c. = subcutaneous; STEMI = ST-segment elevation myocardial infarction; UFH = unfractionated heparin. *Class of recommendation.

¹Clopidogrel is the P2Y₁₂ inhibitor of choice as co-adjuvant and after fibrinolysis, but 48h after fibrinolysis, switch to prasugrel/ticagrelor may be considered in patients who underwent PCI.


	COR	LOE	References
Antiplatelet therapy	10100000	7-0147	
Aspirin			
162- to 325-mg loading dose	1	A	(308,330,331)
81- to 325-mg daily maintenance dose (indefinite)	1	A	(308,330,331)
B1 mg daily is the preferred maintenance dose	lla	B	(254,257,263,264)
P2Y ₁₂ receptor inhibitors		-	
Clopidogrel:	- E	А	(330,331)
Age ≤75 y: 300-mg loading dose			Webble of a
. Followed by 75 mg daily for at least 14 d and up to 1 y in absence of bleeding	t i	A (14 d)	(330,331)
		C (up to 1 y)	N/A
Age >75 y: no loading dose, give 75 mg	1	A	(330,331)
· Followed by 75 mg daily for at least 14 d and up to 1 y in absence of bleeding	1	A (14 d)	(330,331)
		C (up to 1 y)	N/A
Anticoagulant therapy			
• UFH:	1 I	C	N/A
 Weight-based IV bolus and infusion adjusted to obtain aPTT of 1.5 to 2.0 times control for 48 h or until revascularization. IV bolus of 60 U/kg (maximum 4000 U) followed by an infusion of 12 U/kg/h (maximum 1000 U) initially, adjusted to maintain aPTT at 1.5 to 2.0 times control (approximately 50 to 70 s) for 48 h or until revascularization 			
Enoxaparin:	L)	A	(332-335)
 If age <75 y: 30-mg N bolus, followed in 15 min by 1 mg/kg subcutaneously every 12 h (maximum 100 mg for the first 2 doses) 			inter percenti
 If age ≥75 y: no bolus, 0.75 mg/kg subcutaneously every 12 h (maximum 75 mg for the first 2 doses) 			
Regardless of age, if CrCl <30 mL/min: 1 mg/kg subcutaneously every 24 h			
Duration: For the index hospitalization, up to 8 d or until revascularization			
Fondaparinux:	1	В	(304)
 Initial dose 2.5 mg IV, then 2.5 mg subcutaneously daily starting the following day, for the index hospitalization up to 8 d or until revascularization 			
Contraindicated If CrCl < 30 mL/min			


aPTT indicates activated partial thromboplastin time; COR, Class of Recommendation; CrCI, creatinine clearance; IV, intravenous; LOE, Level of Evidence; N/A, not available; and UFH, unfractionated heparin.

Eur Heart J. 2018 Jan 7;39(2):119-177.

Circulation. 2013 Jan 29;127(4):e362-425.

^{*}Level of evidence.





Echo: LVEF 46% LDL: 184

Medications on Discharge Atorvastatin 80 Zetia 10 Losartan 25 Spironolactone 25 Aspirin 81mg **Ticagrelor 90 bid**

Questions

The following is true about PCI of non-culprit lesions in patient presenting with STEMI

- A. Non-culprit lesions should always be treated during the index procedure
- B. Non-culprit lesions should be treated in patients presenting with shock to improve LV Function
- C. Non-culprit lesion PCI in an appropriate setting has a Class IIA indication
- D. Treating non-culprit lesions in patient with cardiogenic improves LVEF
- E. Non-culprit lesion PCI can be performed during the index procedure

The following is true about thrombolysis

- A. Lytics can be given in patients with very high risk NSTEMI because of high clot burden
- B. Thrombolysis in is contraindicated in patients aged over 80.
- C. Administration of lytic is relatively contraindicated in women undergoing menstration
- D. Loading dose of clopidogrel should always be given after thrombolytics
- E. Patients should undergo angiography immediately after lytic therapy

When using triple, use Plavix Limit duration to 30 days PPI

- 1. priorAF on anticoagulation and the need for PCI
- 2. new-onset AF requiringanticoagulation in a patient already on antiplatelet therapy for coronary arterydisease (CAD)
- 3. prior VTE on anticoagulation and the need for PCI
- 4. new or recurrent VTE requiring anticoagulation in a patient already onantiplatelet therapy for CAD.